STOCK TITAN

Stoke Therapeutics Inc - STOK STOCK NEWS

Welcome to our dedicated news page for Stoke Therapeutics (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stoke Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stoke Therapeutics's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
conferences
Stoke Therapeutics Inc

Nasdaq:STOK

STOK Rankings

STOK Stock Data

632.74M
33.69M
5.19%
98.02%
8.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bedford

About STOK

stoke is developing antisense oligonucleotide medicines that target rna splicing to increase gene expression for the treatment of severe genetic diseases.